A Phase I/II, Multicenter, Open-label, Single-arm Study of LDK378, Administered Orally in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib Study Type: Interventional
Phase of Trial: Phase I/II
Latest Information Update: 22 Feb 2019
Price : $35 *
At a glance
- Drugs Ceritinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Novartis Pharmaceuticals Corporation
- 31 Aug 2018 Biomarkers information updated
- 09 Nov 2017 Status changed from active, no longer recruiting to completed.
- 27 Feb 2017 Planned End Date changed from 1 Dec 2016 to 30 Jun 2017.